CREBBP and adrenal cortex carcinoma: Ho et al. also demonstrated that 7% of ACC patients possessed a CREBBP mutation, a histone acetyltransferase enabling transcription across critical signalling pathways, had been mutated in 7% of patients in previous ACC studies [12].